Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- National Cancer Center’s Fujiwara Named New PMDA Chief
March 27, 2019
- Gilead’s HIV Triplet Biktarvy to Join NHI Price List on April 3
March 27, 2019
- MHLW Approves Vyvanse, Biktarvy, Trelegy, Vyndaqel, Dupixent Asthma Use and More
March 27, 2019
- Japan Clears Second Enbrel Biosimilars
March 27, 2019
- PMDA’s Preventative Measures for Document Losses Focus on Traceability, Digitalizing
March 27, 2019
- Japan’s Direct Patient ADR Reporting System Now in Full Operation
March 27, 2019
- Nesp Biosame Likely to Be Priced at 70% of Originator as Stopgap Measure
March 26, 2019
- JMA Reps Oppose Reclassification of Epadel OTC despite No Serious ADR Reports: MHLW Safety Panel
March 26, 2019
- Patient ADR Reporting System to Go into Full-Scale Operation by March-End
March 26, 2019
- PMDA Chief Kondo to Step Down after 11 Years in Charge
March 25, 2019
- “Drugs for Specific Use” under Amended PMD Law Covers Pediatric Use, Antimicrobial Resistance: Official
March 22, 2019
- LDP Lawmakers Not So Positive about Reflecting Societal Values to Drug Prices; They Don’t Know How
March 22, 2019
- MHLW Orders Label Revisions for Takecab, Clozapine and More
March 20, 2019
- Japan Cabinet OKs Bill to Amend PMD Law
March 20, 2019
- Generic Drug Use Rates Particularly Low for Insurance Societies of Research-Driven Drug Makers: MHLW
March 20, 2019
- MHLW Council Rejects OTC Switches of 4 Alzheimer’s Drugs
March 19, 2019
- MHLW Council Recommends OTC Switch of Polycarbophil Calcium
March 19, 2019
- PMD Bill Clears LDP Review, Cabinet OK Slated for March 19
March 18, 2019
- MHLW Council to Draft Negotiation Rules on Supply of Unapproved Drugs under Patient-Initiated Mix Care Scheme
March 18, 2019
- Japan Cabinet OKs PMDA Review Fee Rise from April 1
March 18, 2019
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…